Gout: Diagnosis and Management in Primary Care
Key Takeaways
- Gout affects an estimated 9.2 million Americans, yet it remains underdiagnosed in primary care (CDC, 2022)
- Joint aspiration (synovial fluid analysis) is the gold standard for diagnosis; uric acid blood tests alone are unreliable during an active flare
- The ACR recommends a serum urate target below 6 mg/dL for most patients on urate-lowering therapy (ACR Guidelines, 2020)
- Starting allopurinol can paradoxically trigger more flares; prophylactic colchicine for 3-6 months reduces that risk
- Fewer than 50% of gout patients remain on urate-lowering therapy at one year (Arthritis Care and Research, 2021)
Gout is one of the oldest documented diseases in medicine, yet it's still being mismanaged at scale. Nearly 9.2 million Americans live with gout, according to the CDC, but a significant portion never receive a confirmed diagnosis or a treatment plan that actually controls their uric acid long-term. Primary care physicians see most gout patients long before a rheumatologist ever does.
This guide walks through the full clinical picture: recognizing a flare, making a confident diagnosis, treating acute attacks, and building a long-term urate-lowering strategy that patients will actually stick with.
What Does a Gout Flare Actually Feel Like?
Gout attacks are among the most distinctive presentations in clinical medicine. The classic picture is sudden, severe joint pain in the first metatarsophalangeal joint (the big toe), affecting roughly 50-60% of first presentations (New England Journal of Medicine, 2011). Pain typically peaks within 6-12 hours of onset and is often described as feeling like the joint is on fire.
Timing. Attacks most often begin at night or in the early morning hours. Cooler peripheral temperatures and overnight dehydration both lower the solubility threshold for monosodium urate crystals.
Redness and warmth. The overlying skin becomes erythematous, warm, and stretched. In severe cases it can look almost cellulitic, which sometimes leads to unnecessary antibiotic prescriptions.
Rapid progression. Within hours of onset, even light touch on the affected joint becomes intolerable. Patients often report they can't bear the weight of a bedsheet.
Resolution. Untreated, most acute attacks resolve spontaneously within 7-14 days. This self-limiting nature is one reason gout goes undertreated — patients feel better and stop following up.
Polyarticular gout is less dramatic but harder to diagnose. It's more common in older patients, women, and those on diuretics. The ankle, knee, wrist, and small joints of the hands are involved in these cases, sometimes mimicking rheumatoid arthritis.
Many patients report seeing two or three doctors before getting a definitive gout diagnosis. If a patient presents with a joint that swelled up red and hot overnight and then improved over a week, that history carries substantial diagnostic weight even before any test is run.
How Doctors Diagnose Gout in Primary Care
The gold standard for diagnosing gout is synovial fluid analysis, which identifies negatively birefringent monosodium urate crystals under polarized light microscopy. Studies show that crystal-proven diagnosis is achieved in only about 11% of primary care gout diagnoses, largely because joint aspiration is underutilized in office settings (Annals of the Rheumatic Diseases, 2015).
Joint Aspiration: The Gold Standard Worth Doing
Aspiration of an affected joint provides definitive confirmation and lets you rule out septic arthritis, which is the most dangerous condition on the differential. The procedure is straightforward for accessible joints like the knee and first MTP. You should also send fluid for Gram stain and culture, because gout and septic arthritis can coexist.
Serum Uric Acid: Useful, But Not During a Flare
Serum urate is the most commonly ordered test, but it has a critical limitation. During an acute attack, uric acid levels drop in up to 40% of patients due to the inflammatory response (ACR, 2020). A normal or low uric acid during a flare does not rule out gout. Conversely, hyperuricemia alone doesn't confirm gout; only 20% of people with elevated uric acid will ever have a gout attack. The most useful window for serum urate measurement is at least 4-6 weeks after an acute flare resolves.
Imaging Alternatives
Musculoskeletal ultrasound has become a practical alternative in primary care. The "double contour sign" has a reported sensitivity of around 77% and specificity of 84% for gout (Arthritis and Rheumatology, 2015). Dual-energy CT can visualize urate deposits with high accuracy but is expensive and not widely available in primary care.
How to Treat an Acute Gout Attack
The goal is to stop the inflammatory cascade as quickly as possible. Treatment started within 24 hours of symptom onset is substantially more effective than delayed therapy (BMJ Best Practice, 2023). Patients should keep their medication at home and start it immediately at the first sign of a flare, without waiting for an office visit.
NSAIDs: First-Line When There Are No Contraindications
Full-dose NSAIDs remain the preferred first-line option. Indomethacin (50 mg three times daily) and naproxen (500 mg twice daily) are the most studied. Treatment typically continues until the flare fully resolves, usually 5-7 days.
NSAIDs are contraindicated in active peptic ulcer disease, GFR below 30 mL/min, or significant cardiovascular disease. In those patients, move directly to colchicine or corticosteroids.
Colchicine: Highly Effective at Low Dose
Low-dose colchicine is as effective as high-dose regimens with far fewer GI side effects. The ACR-recommended protocol is 1.2 mg at symptom onset, followed by 0.6 mg one hour later (NEJM, 2010). Colchicine is a CYP3A4 substrate — use caution with clarithromycin, cyclosporine, and reduce the dose in renal impairment.
Corticosteroids: The Backup Option That Works
Oral prednisone (30-35 mg/day for 5 days) is an effective option when NSAIDs and colchicine are both contraindicated. Intra-articular corticosteroid injection provides rapid relief for monoarticular involvement and is underused in primary care.
Urate-Lowering Therapy: Who Needs It and When?
Urate-lowering therapy (ULT) is the cornerstone of long-term gout management, but it's initiated in far fewer patients than guidelines recommend. Fewer than 40% of eligible patients in primary care are ever prescribed it (Arthritis Care and Research, 2020).
The ACR 2020 guidelines strongly recommend initiating ULT for:
- Two or more gout flares per year
- Presence of tophi
- Chronic kidney disease stage 3 or higher
- History of nephrolithiasis from uric acid
ULT is conditionally recommended after a first flare in patients with serum urate persistently above 9 mg/dL or evidence of joint damage on imaging.
Starting Allopurinol Correctly
Start low and go slow. Begin at 100 mg/day (50 mg/day in CKD stage 3 or higher), then titrate by 100 mg every 2-5 weeks until serum urate falls below 6 mg/dL. The target is 5 mg/dL in patients with tophi.
Febuxostat is an alternative for patients who can't tolerate allopurinol, but note the FDA black box warning: febuxostat carries a higher risk of cardiovascular mortality compared to allopurinol in patients with established cardiovascular disease.
The Flare Paradox: Why Starting Allopurinol Can Make Gout Worse
When serum urate drops rapidly, crystals sitting stably in joint tissues begin to dissolve and shed into the synovial fluid. The immune system detects these crystals and mounts an inflammatory response. The result looks and feels exactly like a new gout attack.
Prophylactic Colchicine Reduces This Risk Dramatically
The ACR recommends anti-inflammatory prophylaxis for the first 3-6 months of ULT. Low-dose colchicine (0.6 mg once or twice daily) reduces flare frequency during this period by approximately 85% (Arthritis and Rheumatology, 2012).
This is the conversation patients most need before starting allopurinol. Without it, the first flare on medication feels like treatment failure and the patient stops. With it, the flare is expected, manageable, and understood as a sign the medication is working.
Which Lifestyle Changes Actually Help?
Not all dietary changes carry equal weight. The evidence base is more nuanced than most patient handouts suggest.
Weight loss. Each 5 kg of weight loss reduces serum urate by approximately 0.5 mg/dL (Annals of the Rheumatic Diseases, 2019). Even modest reduction matters.
Alcohol reduction. Beer and spirits are the most problematic — they contain purines and promote urate retention. Wine has a weaker association in moderate amounts. Total abstinence is ideal during flares.
Diet. Red meat (especially organ meats) and shellfish have the highest purine loads. Low-fat dairy products are actually uricosuric and modestly reduce gout risk. The DASH diet pattern is associated with lower uric acid levels and is a reasonable framework.
Hydration. Target 2-3 liters of water per day, with higher volumes for patients with kidney stones.
Vitamin C. Some observational studies suggest modest uric acid lowering. The effect is small, and high-dose supplementation can increase oxalate kidney stone risk — don't lead with this recommendation.
Comorbidities to Manage Alongside Gout
Roughly 74% of gout patients have hypertension, 71% have CKD, and 26% have diabetes. Managing these conditions is inseparable from managing gout well.
Hypertension. Thiazide diuretics raise serum urate and should be avoided as first-line antihypertensives in gout patients when alternatives exist. Losartan is the preferred choice — it has a mild uricosuric effect and can lower serum urate by 0.5-1.0 mg/dL at standard doses. Amlodipine and other calcium channel blockers are urate-neutral.
Chronic kidney disease. CKD reduces renal urate excretion and accelerates crystal deposition. Allopurinol can still be used in CKD — start at 50 mg/day and titrate carefully. Febuxostat may be preferred in moderate CKD because it's primarily hepatically metabolized.
A gout diagnosis is also an opportunity to run a full cardiovascular and metabolic panel. Patients with gout are statistically likely to be at elevated cardiac risk regardless of their traditional risk factors.
Frequently Asked Questions
Should I stop allopurinol during a gout flare?
No. The ACR and most rheumatology guidelines recommend continuing allopurinol during an acute flare. Stopping and restarting ULT causes repeated serum urate fluctuations, which can prolong or re-trigger flares through the crystal mobilization mechanism. Treat the flare with anti-inflammatory therapy while keeping ULT constant.
How long does it take for allopurinol to start working?
Allopurinol begins lowering serum urate within days, but reaching and sustaining the target below 6 mg/dL often takes 3-6 months of careful dose titration. Clinical benefits, like fewer flares and reduced tophi burden, take longer. Patients need realistic expectations: gout management is a long-term commitment, not a quick fix.
Can I drink alcohol on colchicine?
Alcohol isn't directly contraindicated with colchicine, but it's strongly inadvisable. Alcohol raises uric acid through multiple mechanisms: it promotes purine synthesis, reduces renal uric acid excretion, and dehydrates the body. During a flare or early ULT initiation, alcohol can worsen outcomes. Moderation or abstinence is the evidence-supported recommendation.
Is gout hereditary?
Genetics play a meaningful role. Variants in urate transporter genes (particularly SLC22A12, SLC2A9, and ABCG2) are strongly associated with hyperuricemia and gout risk. Having a first-degree relative with gout increases lifetime risk considerably. Lifestyle factors can significantly modify genetic predisposition, making diet and medication compliance highly relevant even in genetically susceptible individuals.
Managing Gout for the Long Haul
Gout is one of the few truly curable forms of arthritis — sustained serum urate below 6 mg/dL dissolves existing crystal deposits over time, reduces flare frequency, and prevents progressive joint damage. The challenge isn't pharmacology; it's adherence.
Patients who understand the mechanism, know that initial flares on allopurinol are expected, and have a concrete monitoring plan (uric acid every 4-6 weeks during titration, then every 6 months once stable) are far more likely to stay on therapy.
If you're managing your gout day-to-day and want to track what you eat, identify your food triggers, and stay on top of your uric acid patterns, the GoutSnap app can help. It includes an AI food scanner, a gout flare tracker, and personalized dietary guidance.